A citation-based method for searching scientific literature

Colin M Dayan, Maria Korah, Danijela Tatovic, Brian N Bundy, Kevan C Herold. Lancet 2019
Times Cited: 17







List of co-cited articles
63 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Kevan C Herold, Brian N Bundy, S Alice Long, Jeffrey A Bluestone, Linda A DiMeglio, Matthew J Dufort, Stephen E Gitelman, Peter A Gottlieb, Jeffrey P Krischer, Peter S Linsley,[...]. N Engl J Med 2019
143
41

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Richard A Insel, Jessica L Dunne, Mark A Atkinson, Jane L Chiang, Dana Dabelea, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jeffrey P Krischer, Åke Lernmark,[...]. Diabetes Care 2015
286
29

Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
918
23


Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Michael W Steffes, Shalamar Sibley, Melissa Jackson, William Thomas. Diabetes Care 2003
417
23

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2013
175
23

Early prediction of autoimmune (type 1) diabetes.
Simon E Regnell, Åke Lernmark. Diabetologia 2017
52
17

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Mark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Paula F McGee, Antoinette M Moran,[...]. N Engl J Med 2009
600
17

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
336
17

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.
Asa K Davis, Stephanie N DuBose, Michael J Haller, Kellee M Miller, Linda A DiMeglio, Kathleen E Bethin, Robin S Goland, Ellen M Greenberg, David R Liljenquist, Andrew J Ahmann,[...]. Diabetes Care 2015
104
17

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,[...]. N Engl J Med 2005
737
17

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
S Alice Long, Jerill Thorpe, Hannah A DeBerg, Vivian Gersuk, James Eddy, Kristina M Harris, Mario Ehlers, Kevan C Herold, Gerald T Nepom, Peter S Linsley. Sci Immunol 2016
64
17

Genetics, pathogenesis and clinical interventions in type 1 diabetes.
Jeffrey A Bluestone, Kevan Herold, George Eisenbarth. Nature 2010
617
17

The human gut microbiome in early-onset type 1 diabetes from the TEDDY study.
Tommi Vatanen, Eric A Franzosa, Randall Schwager, Surya Tripathi, Timothy D Arthur, Kendra Vehik, Åke Lernmark, William A Hagopian, Marian J Rewers, Jin-Xiong She,[...]. Nature 2018
184
11

Innate immunity and intestinal microbiota in the development of Type 1 diabetes.
Li Wen, Ruth E Ley, Pavel Yu Volchkov, Peter B Stranges, Lia Avanesyan, Austin C Stonebraker, Changyun Hu, F Susan Wong, Gregory L Szot, Jeffrey A Bluestone,[...]. Nature 2008
11

Environmental risk factors for type 1 diabetes.
Marian Rewers, Johnny Ludvigsson. Lancet 2016
220
11

Advances in β-cell replacement therapy for the treatment of type 1 diabetes.
Marie-Christine Vantyghem, Eelco J P de Koning, François Pattou, Michael R Rickels. Lancet 2019
29
11

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients.
Bart Keymeulen, Sophie Candon, Samira Fafi-Kremer, Anette Ziegler, Marianne Leruez-Ville, Chantal Mathieu, Evy Vandemeulebroucke, Markus Walter, Laurent Crenier, Eric Thervet,[...]. Blood 2010
54
11

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A Dimeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Diabetes Care 2014
102
11

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Carla J Greenbaum, Craig A Beam, David Boulware, Stephen E Gitelman, Peter A Gottlieb, Kevan C Herold, John M Lachin, Paula McGee, Jerry P Palmer, Mark D Pescovitz,[...]. Diabetes 2012
180
11

Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Ronnie Aronson, Peter A Gottlieb, Jens S Christiansen, Thomas W Donner, Emanuele Bosi, Bruce W Bode, Paolo Pozzilli. Diabetes Care 2014
66
11

Immune modulation in humans: implications for type 1 diabetes mellitus.
Bart O Roep, Timothy I M Tree. Nat Rev Endocrinol 2014
81
11

B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.
Peter S Linsley, Carla J Greenbaum, Cate Speake, S Alice Long, Matthew J Dufort. JCI Insight 2019
17
11

CTLA-4 can function as a negative regulator of T cell activation.
T L Walunas, D J Lenschow, C Y Bakker, P S Linsley, G J Freeman, J M Green, C B Thompson, J A Bluestone. Immunity 1994
11

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin,[...]. Lancet 2011
280
11

Residual β cell function and monogenic variants in long-duration type 1 diabetes patients.
Marc Gregory Yu, Hillary A Keenan, Hetal S Shah, Scott G Frodsham, David Pober, Zhiheng He, Emily A Wolfson, Stephanie D'Eon, Liane J Tinsley, Susan Bonner-Weir,[...]. J Clin Invest 2019
22
11

Lack of association between residual insulin production and glucagon response to hypoglycemia in youth with short duration of type 1 diabetes.
Jennifer Sherr, Dongyuan Xing, Katrina J Ruedy, Roy W Beck, Craig Kollman, Bruce Buckingham, Neil H White, Larry Fox, Eva Tsalikian, Stuart Weinzimer,[...]. Diabetes Care 2013
20
11

Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY).
Andrea K Steck, Kendra Vehik, Ezio Bonifacio, Ake Lernmark, Anette-G Ziegler, William A Hagopian, JinXiong She, Olli Simell, Beena Akolkar, Jeffrey Krischer,[...]. Diabetes Care 2015
77
11


Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study.
Hillary A Keenan, Jennifer K Sun, Jared Levine, Alessandro Doria, Lloyd P Aiello, George Eisenbarth, Susan Bonner-Weir, George L King. Diabetes 2010
289
11

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.
Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith,[...]. Diabetes Technol Ther 2019
411
11

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.
Michael J Haller, Desmond A Schatz, Jay S Skyler, Jeffrey P Krischer, Brian N Bundy, Jessica L Miller, Mark A Atkinson, Dorothy J Becker, David Baidal, Linda A DiMeglio,[...]. Diabetes Care 2018
33
11

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
Jeffrey P Krischer, Desmond A Schatz, Brian Bundy, Jay S Skyler, Carla J Greenbaum. JAMA 2017
56
11

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Mark R Rigby, Kristina M Harris, Ashley Pinckney, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Kurt J Griffin, Eva Tsalikian,[...]. J Clin Invest 2015
127
11

The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study.
Jeffrey P Krischer, Kristian F Lynch, Desmond A Schatz, Jorma Ilonen, Åke Lernmark, William A Hagopian, Marian J Rewers, Jin-Xiong She, Olli G Simell, Jorma Toppari,[...]. Diabetologia 2015
180
11

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin,[...]. N Engl J Med 2002
777
11

Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies.
G F Bottazzo, A Florin-Christensen, D Doniach. Lancet 1974
843
11

B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Mark D Pescovitz, Carla J Greenbaum, Brian Bundy, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Antoinette Moran, Philip Raskin,[...]. Diabetes Care 2014
112
11

Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes.
Kerry A McLaughlin, Carolyn C Richardson, Aarthi Ravishankar, Cristina Brigatti, Daniela Liberati, Vito Lampasona, Lorenzo Piemonti, Diana Morgan, Richard G Feltbower, Michael R Christie. Diabetes 2016
47
11

Generation of functional human pancreatic β cells in vitro.
Felicia W Pagliuca, Jeffrey R Millman, Mads Gürtler, Michael Segel, Alana Van Dervort, Jennifer Hyoje Ryu, Quinn P Peterson, Dale Greiner, Douglas A Melton. Cell 2014
918
11

Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.
Araz Rawshani, Naveed Sattar, Stefan Franzén, Aidin Rawshani, Andrew T Hattersley, Ann-Marie Svensson, Björn Eliasson, Soffia Gudbjörnsdottir. Lancet 2018
157
11

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Carlos E B Couri, Maria C B Oliveira, Ana B P L Stracieri, Daniela A Moraes, Fabiano Pieroni, George M N Barros, Maria Isabel A Madeira, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2009
243
11

Oral tolerance:Recent advances on mechanisms and potential applications.
Thaniya Sricharunrat, Pornpan Pumirat, Pornsawan Leaungwutiwong. Asian Pac J Allergy Immunol 2018
4
50

Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
Ezio Bonifacio, Anette-G Ziegler, Georgeanna Klingensmith, Edith Schober, Polly J Bingley, Marietta Rottenkolber, Anke Theil, Anne Eugster, Ramona Puff, Claudia Peplow,[...]. JAMA 2015
89
11

Induction of mucosal tolerance in Peyer's patch-deficient, ligated small bowel loops.
Thomas A Kraus, Jens Brimnes, Christine Muong, Jian-Hua Liu, Thomas M Moran, Kelly A Tappenden, Peter Boros, Lloyd Mayer. J Clin Invest 2005
61
11

An epidemiological overview of diabetes across the world.
Danny Meetoo, Peter McGovern, Reema Safadi. Br J Nurs 2007
65
11


Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells.
Tim Worbs, Ulrike Bode, Sheng Yan, Matthias W Hoffmann, Gabriele Hintzen, Günter Bernhardt, Reinhold Förster, Oliver Pabst. J Exp Med 2006
421
11

Type 1 diabetes.
Linda A DiMeglio, Carmella Evans-Molina, Richard A Oram. Lancet 2018
160
11

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Jay S Skyler, Jeffrey P Krischer, Joseph Wolfsdorf, Catherine Cowie, Jerry P Palmer, Carla Greenbaum, David Cuthbertson, Lisa E Rafkin-Mervis, H Peter Chase, Ellen Leschek. Diabetes Care 2005
372
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.